gantenerumab: Clinical Trials

7 completed. 7 Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	7	Completed 7

Follow gantenerumab: new trials by email Literature Review of gantenerumab trials Research Report on gantenerumab

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants Gantenerumab - Healthy Participants	Phase 1	Completed	Hoffmann-La Roche	114	2017-08-01	2018-12-12
A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants Gantenerumab, Placebo - Healthy Volunteer	Phase 1	Completed	Hoffmann-La Roche	48	2016-08-31	2019-06-11
A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers Gantenerumab, Placebo - Healthy Volunteer	Phase 1	Completed	Hoffmann-La Roche	18	2016-03-31	2019-04-10
A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers gantenerumab - Healthy Volunteer	Phase 1	Completed	Hoffmann-La Roche	31	2014-04-01	2016-11-02
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients Gantenerumab, Placebo - Alzheimer's Disease	Phase 1	Completed	Chugai Pharmaceutical	28	2012-06-01	2014-09-19
A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers gantenerumab - Healthy Volunteer	Phase 1	Completed	Hoffmann-La Roche	120	2012-05-01	2016-11-02
A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease. gantenerumab - Alzheimer's Disease	Phase 1	Completed	Hoffmann-La Roche	60	2006-12-01	2016-11-02

Conditions studied

Alzheimer Disease (2)

Sponsors

Hoffmann-La Roche (6)  ·  Chugai Pharmaceutical (1)

Countries

United States (4)  ·  Denmark (1)  ·  France (1)  ·  Israel (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Sweden (1)  ·  United Kingdom (1)

Results publications

PMID 31883703

NIH funding

2015 (1)